…
EvokAI Creative Labs Inc., a MedTech artificial-intelligence (AI)-powered company, engages in the development of transformational technologies for the healthcare sector. The company's artificial intelligence-enhanced diagnostic profiles provide a basis to monitor mental wellbeing and enable advances in medical diagnoses. It deploys machine learning models to search medical data, integrate novel medical devices, and uncover insights to help improve health outcomes, patient experiences, drug development, preclinical and clinical decisions, and provide accurate diagnoses. The company also provides EvokAI Simulators, which combine cognitive neuroscience, virtual reality (VR), and AI technologies to assess cognitive performance and spatial perception; EvokAI Movement Disorder Monitor (MDM) Basic, a wireless and real-time monitor that accurately analyzes the magnitude of movement disorders and the effectiveness of treatments for Parkinson´s disease and other movement disorders, such as dystonia, various diseases causing tremors, Tourette´s syndrome, congenial CP, or MS; and EvokAI MDM PRO, which is used to monitor movement disorders in real time for the accurate surgical results. In addition, it offers EvokAI Neurotrainer, which provides brain health solutions for various ages; and EvokAI Medical, which offers mental wellbeing through AI-driven digital solutions. The company is headquartered in Vancouver, Canada. EvokAI Creative Labs Inc. is a subsidiary of Union Acquisition Group, LLC.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
EvokAI Creative Labs Inc. has limited public disclosures but identifies as a developer of AI-driven creative tools and services for content production. Long-term growth may be supported by rising adoption of generative AI, successful product commercialization and partnerships with creators or enterprises, which could make the company an avenue for early-stage exposure to the AI content tools market.
Material investment risks include a limited operating and disclosure history, intense competition from larger AI and software firms, execution and commercialization risk, and likely need for additional financing that could dilute existing shareholders.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -17.08M | -0.72M | -0.09M |
| Net income | -17.08M | -0.72M | -0.09M |
| Selling general administrative | 1.85M | 0.30M | 0.01M |
| Operating income | -2.34M | -0.72M | -0.09M |
| Interest expense | 0.02M | 0.00M | - |
| Net interest income | -0.02M | 0.00M | - |
| Total revenue | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 2.34M | 0.72M | 0.09M |
| Total other income expense net | -14.72M | - | - |
| Net income from continuing ops | -17.08M | -0.72M | -0.09M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 0.87M | 0.00M | 0.06M |
| Total liab | 1.16M | 0.66M | 0.00M |
| Total stockholder equity | -0.28M | -0.66M | 0.06M |
| Capital stock | 18.76M | 3.64M | 3.64M |
| Retained earnings | -21.39M | -4.30M | -3.59M |
| Cash | 0.77M | 0.00M | 0.01M |
| Total current liabilities | 0.48M | 0.66M | 0.00M |
| Net debt | 0.01M | 0.04M | - |
| Short long term debt | 0.11M | 0.05M | - |
| Total current assets | 0.87M | 0.00M | 0.06M |
| Net receivables | 0.03M | 0.00M | 0.00M |
| Long term debt | 0.68M | - | - |
| Accounts payable | - | 0.16M | 0.01M |
| Non current assets total | 0.00M | 0.00M | 0.00M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Net borrowings | -0.11M | 0.00M | 0.00M |
| Total cash from financing activities | -0.11M | 0.00M | 0.00M |
| Net income | -17.08M | -0.72M | -0.09M |
| Change in cash | 0.77M | -0.00M | -0.09M |
| Begin period cash flow | 0.00M | 0.01M | 0.13M |
| End period cash flow | 0.77M | 0.00M | 0.04M |
| Total cash from operating activities | -2.53M | -0.00M | -0.09M |
| Issuance of capital stock | - | 0.24M | 0.00M |
| Change to account receivables | -0.06M | 0.00M | - |
| Capital expenditures | 0.00M | 0.00M | 0.00M |
| Change in working capital | -0.80M | 0.71M | -0.00M |
| Stock based compensation | 0.61M | 0.00M | - |
| Other non cash items | 2.08M | 0.00M | - |
| Free cash flow | -2.53M | -0.00M | -0.09M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| NURS Hydreight Technologies Inc |
0.09 3.20% |
2.90 | 406.00 | 25.91 | 7.85 | 20.38 | 109.02 |
| ADK Diagnos Inc |
0.01 1.41% |
0.36 | - | 10.00 | 411.24 | 18.74 | -6.16 |
| NXG NexgenRX Inc. |
- -% |
0.66 | 39.00 | 32.68 | 1.55 | 4.64 | 7.84 |
| PTEC Principal Technologies Inc |
- -% |
0.32 | - | - | 62.75 | 355.42 | -0.81 |
EvokAI Creative Labs Inc., a MedTech artificial-intelligence (AI)-powered company, engages in the development of transformational technologies for the healthcare sector. The company's artificial intelligence-enhanced diagnostic profiles provide a basis to monitor mental wellbeing and enable advances in medical diagnoses. It deploys machine learning models to search medical data, integrate novel medical devices, and uncover insights to help improve health outcomes, patient experiences, drug development, preclinical and clinical decisions, and provide accurate diagnoses. The company also provides EvokAI Simulators, which combine cognitive neuroscience, virtual reality (VR), and AI technologies to assess cognitive performance and spatial perception; EvokAI Movement Disorder Monitor (MDM) Basic, a wireless and real-time monitor that accurately analyzes the magnitude of movement disorders and the effectiveness of treatments for Parkinson´s disease and other movement disorders, such as dystonia, various diseases causing tremors, Tourette´s syndrome, congenial CP, or MS; and EvokAI MDM PRO, which is used to monitor movement disorders in real time for the accurate surgical results. In addition, it offers EvokAI Neurotrainer, which provides brain health solutions for various ages; and EvokAI Medical, which offers mental wellbeing through AI-driven digital solutions. The company is headquartered in Vancouver, Canada. EvokAI Creative Labs Inc. is a subsidiary of Union Acquisition Group, LLC.
609 Granville Street, Vancouver, BC, Canada, V7Y 1C3
| Name | Title | Year Born |
|---|---|---|
| Mr. Alejandro Antalich | CEO & Director | 1974 |
| Mr. Scott Edwin Ackerman | CFO, Corporate Secretary & Director | 1967 |
| Mr. Rauno Jokelainen | Operations Manager | NA |
| Dr. Georg Meissner | Executive Vice President of Digital Health Research & Technology | NA |
| Ms. Tuula Palmen | Chief Business Officer | NA |
| Mr. Hans J. Lauterbach | President of Europe, Asia Pacific & Middle East | NA |
| Mr. Alejandro Antalich | CEO & Director | 1973 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.